Lilly Medical US
@lillymedical.bsky.social
Lilly Medical’s official social channel connecting U.S. healthcare providers with our latest scientific updates, shared by trusted Lilly HCPs. Social Guidelines: e.lilly/guidelines
I'm sharing new data from the real-world effectiveness of a single versus a dual incretin receptor agonist on HbA1c and weight in patients with type 2 diabetes study, now published in Diabetes Therapy.
Click here to read the full study: e.lilly/3WNj1IP
#MedSky #EndoSky
Click here to read the full study: e.lilly/3WNj1IP
#MedSky #EndoSky
November 24, 2025 at 6:16 PM
I'm sharing new data from the real-world effectiveness of a single versus a dual incretin receptor agonist on HbA1c and weight in patients with type 2 diabetes study, now published in Diabetes Therapy.
Click here to read the full study: e.lilly/3WNj1IP
#MedSky #EndoSky
Click here to read the full study: e.lilly/3WNj1IP
#MedSky #EndoSky
I’m sharing results from a secondary analysis of TRAILBLAZER-ALZ 2, a randomized clinical trial on posttreatment amyloid levels and clinical outcomes following amyloid-targeting therapy for early symptomatic Alzheimer’s disease. #MedSky #NeuroSky
Learn more about our latest findings: e.lilly/47YrWfO
Learn more about our latest findings: e.lilly/47YrWfO
November 14, 2025 at 9:49 PM
I’m sharing results from a secondary analysis of TRAILBLAZER-ALZ 2, a randomized clinical trial on posttreatment amyloid levels and clinical outcomes following amyloid-targeting therapy for early symptomatic Alzheimer’s disease. #MedSky #NeuroSky
Learn more about our latest findings: e.lilly/47YrWfO
Learn more about our latest findings: e.lilly/47YrWfO
I'm sharing new research on the SURPASS-PEDS Phase 3 Study: Efficacy and Safety of an Incretin Receptor Agonist in Children and Adolescents with Type 2 Diabetes
Click here to read the full study: e.lilly/4quJybA
#MedSky #EndoSky
Click here to read the full study: e.lilly/4quJybA
#MedSky #EndoSky
November 7, 2025 at 2:39 AM
I'm sharing new research on the SURPASS-PEDS Phase 3 Study: Efficacy and Safety of an Incretin Receptor Agonist in Children and Adolescents with Type 2 Diabetes
Click here to read the full study: e.lilly/4quJybA
#MedSky #EndoSky
Click here to read the full study: e.lilly/4quJybA
#MedSky #EndoSky
I'm sharing new research on therapeutic inertia in an insured population with type 2 diabetes in the United States: a retrospective cohort study
Click here to read the full study: e.lilly/4gQNEq3
#MedSky #EndoSky
Click here to read the full study: e.lilly/4gQNEq3
#MedSky #EndoSky
October 10, 2025 at 1:00 PM
I'm sharing new research on therapeutic inertia in an insured population with type 2 diabetes in the United States: a retrospective cohort study
Click here to read the full study: e.lilly/4gQNEq3
#MedSky #EndoSky
Click here to read the full study: e.lilly/4gQNEq3
#MedSky #EndoSky
I’m sharing the results of an IL-13 inhibitor and its effect on head and neck Dermatitis and Erythema in ADvocate 1&2 and ADhere Trials. View the full publication here: e.lilly/45IJyuK
#MedSky #DermSky
#MedSky #DermSky
September 21, 2025 at 1:30 PM
I’m sharing the results of an IL-13 inhibitor and its effect on head and neck Dermatitis and Erythema in ADvocate 1&2 and ADhere Trials. View the full publication here: e.lilly/45IJyuK
#MedSky #DermSky
#MedSky #DermSky
I am sharing the latest results of an IL-13 inhibitor on inflammatory biomarkers and clinical correlations in patients with moderate-to-severe Atopic Dermatitis. Now available in the Journal of Dermatology and Therapy. View full publication here: e.lilly/47HFkX1
#MedSky #DermSky
#MedSky #DermSky
September 15, 2025 at 5:33 PM
I am sharing the latest results of an IL-13 inhibitor on inflammatory biomarkers and clinical correlations in patients with moderate-to-severe Atopic Dermatitis. Now available in the Journal of Dermatology and Therapy. View full publication here: e.lilly/47HFkX1
#MedSky #DermSky
#MedSky #DermSky
I’m sharing the latest results from a biologic study in Atopic Dermatitis solely in patients with pigmented skin – Now published in the American Journal of Clinical Dermatology: e.lilly/3JGiWmO
September 8, 2025 at 4:49 PM
I’m sharing the latest results from a biologic study in Atopic Dermatitis solely in patients with pigmented skin – Now published in the American Journal of Clinical Dermatology: e.lilly/3JGiWmO
I’m sharing TRAILBLAZER-ALZ 6 now published in The Journal of Prevention of Alzheimer’s Disease: Modified amyloid-targeting therapy dose titration showed effects on imaging abnormalities (edema/effusions) and amyloid reduction at 18-months.
Learn more: e.lilly/4lNBAHq
#Neuroscience #NeuroSky
Learn more: e.lilly/4lNBAHq
#Neuroscience #NeuroSky
September 5, 2025 at 2:07 PM
I’m sharing TRAILBLAZER-ALZ 6 now published in The Journal of Prevention of Alzheimer’s Disease: Modified amyloid-targeting therapy dose titration showed effects on imaging abnormalities (edema/effusions) and amyloid reduction at 18-months.
Learn more: e.lilly/4lNBAHq
#Neuroscience #NeuroSky
Learn more: e.lilly/4lNBAHq
#Neuroscience #NeuroSky
I am sharing the latest results from a Phase 3 VIVID-1 study on bowel urgency response in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/3Uiqbnc
Click here to read the full publication: e.lilly/3Uiqbnc
September 4, 2025 at 1:30 PM
I am sharing the latest results from a Phase 3 VIVID-1 study on bowel urgency response in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/3Uiqbnc
Click here to read the full publication: e.lilly/3Uiqbnc
I'm sharing new research on how body mass index, central adiposity, and weight loss impact the benefits of an incretin receptor agonist in HFpEF, now published in Journal of the American College of Cardiology.
Click here to read the full study: e.lilly/4fhnMCR
#MedSky #EndoSky
Click here to read the full study: e.lilly/4fhnMCR
#MedSky #EndoSky
August 28, 2025 at 1:30 PM
I'm sharing new research on how body mass index, central adiposity, and weight loss impact the benefits of an incretin receptor agonist in HFpEF, now published in Journal of the American College of Cardiology.
Click here to read the full study: e.lilly/4fhnMCR
#MedSky #EndoSky
Click here to read the full study: e.lilly/4fhnMCR
#MedSky #EndoSky
I’m sharing 52-week outcomes on itch symptoms and sleep interference in moderate-to-severe atopic dermatitis from the ADvocate1 and ADvocate2 Phase 3 trials. View the full publication here: e.lilly/3ITBpvP
August 25, 2025 at 1:30 PM
I’m sharing 52-week outcomes on itch symptoms and sleep interference in moderate-to-severe atopic dermatitis from the ADvocate1 and ADvocate2 Phase 3 trials. View the full publication here: e.lilly/3ITBpvP
I'm sharing new research comparing once-weekly Insulin and once-daily insulin in adults with type 2 diabetes who are currently treated with basal insulin
Click here to read the full study: e.lilly/3ZRHKhc
#MedSky #EndoSky
Click here to read the full study: e.lilly/3ZRHKhc
#MedSky #EndoSky
August 13, 2025 at 8:10 PM
I'm sharing new research comparing once-weekly Insulin and once-daily insulin in adults with type 2 diabetes who are currently treated with basal insulin
Click here to read the full study: e.lilly/3ZRHKhc
#MedSky #EndoSky
Click here to read the full study: e.lilly/3ZRHKhc
#MedSky #EndoSky
Latest QWINT-4 Phase 3 Results Comparing Once-Weekly and Once-Daily Insulin in Adults with Type 2 Diabetes on Basal and Prandial Insulin — Now Published in The Lancet: e.lilly/4eQCxwa
#Diabetes
#Diabetes
August 4, 2025 at 7:02 PM
Latest QWINT-4 Phase 3 Results Comparing Once-Weekly and Once-Daily Insulin in Adults with Type 2 Diabetes on Basal and Prandial Insulin — Now Published in The Lancet: e.lilly/4eQCxwa
#Diabetes
#Diabetes
I am sharing the latest results from a Phase 3 VIVID-1 study on fatigue outcomes in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/4072ul5
Click here to read the full publication: e.lilly/4072ul5
July 31, 2025 at 7:00 PM
I am sharing the latest results from a Phase 3 VIVID-1 study on fatigue outcomes in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/4072ul5
Click here to read the full publication: e.lilly/4072ul5
I’m sharing new data from the ADjoin trial—a 2-year long-term extension study evaluating an IL-13 inhibitor in patients with moderate-to-severe atopic dermatitis. View the full results here: e.lilly/3GpizMw
#MedSky #DermSky
#MedSky #DermSky
July 31, 2025 at 1:30 PM
I’m sharing new data from the ADjoin trial—a 2-year long-term extension study evaluating an IL-13 inhibitor in patients with moderate-to-severe atopic dermatitis. View the full results here: e.lilly/3GpizMw
#MedSky #DermSky
#MedSky #DermSky
I'm sharing new research from the ACHIEVE-1 Phase 3 study of a GLP-1 receptor agonist in early type 2 diabetes, now published in The New England Journal of Medicine.
Click here to read the full study: e.lilly/4lkZqKK
Click here to read the full study: e.lilly/4lkZqKK
July 14, 2025 at 1:00 PM
I'm sharing new research from the ACHIEVE-1 Phase 3 study of a GLP-1 receptor agonist in early type 2 diabetes, now published in The New England Journal of Medicine.
Click here to read the full study: e.lilly/4lkZqKK
Click here to read the full study: e.lilly/4lkZqKK
I'm sharing new research on Weekly Fixed-Dose Insulin in Type 2 Diabetes without Previous Insulin Therapy, now published in NEJM!
Click here to read the full study: e.lilly/4nCNsOb
#MedSky #EndoSky
Click here to read the full study: e.lilly/4nCNsOb
#MedSky #EndoSky
July 9, 2025 at 11:00 AM
I'm sharing new research on Weekly Fixed-Dose Insulin in Type 2 Diabetes without Previous Insulin Therapy, now published in NEJM!
Click here to read the full study: e.lilly/4nCNsOb
#MedSky #EndoSky
Click here to read the full study: e.lilly/4nCNsOb
#MedSky #EndoSky
I'm sharing new scientific insights on a head-to-head study comparing dual and single incretin receptor agonists in obesity treatment: e.lilly/4dMJBto
#MedSky #EndoSky
#MedSky #EndoSky
June 16, 2025 at 7:00 PM
I'm sharing new scientific insights on a head-to-head study comparing dual and single incretin receptor agonists in obesity treatment: e.lilly/4dMJBto
#MedSky #EndoSky
#MedSky #EndoSky
I'm sharing the BRUIN CLL-321 study now out in JCO: The first randomized Ph3 study conducted exclusively in covalent BTKi-pretreated #CLL/SLL, evaluating a non-covalent BTKi vs idelalisib/rituximab or bendamustine/rituximab.
Full results and supplemental resources: e.lilly/4kA96k4
#LeuSky #OncSky
Full results and supplemental resources: e.lilly/4kA96k4
#LeuSky #OncSky
June 13, 2025 at 9:39 PM
I'm sharing the BRUIN CLL-321 study now out in JCO: The first randomized Ph3 study conducted exclusively in covalent BTKi-pretreated #CLL/SLL, evaluating a non-covalent BTKi vs idelalisib/rituximab or bendamustine/rituximab.
Full results and supplemental resources: e.lilly/4kA96k4
#LeuSky #OncSky
Full results and supplemental resources: e.lilly/4kA96k4
#LeuSky #OncSky
I’m sharing new results from SWITCH-1: A comparison of dose escalation of an incretin receptor agonist versus switching to another incretin receptor agonist among people with inadequately controlled type 2 diabetes.
Click here to read the full study: e.lilly/4jkBd6n
#MedSky #EndoSky
Click here to read the full study: e.lilly/4jkBd6n
#MedSky #EndoSky
May 1, 2025 at 12:00 PM
I’m sharing new results from SWITCH-1: A comparison of dose escalation of an incretin receptor agonist versus switching to another incretin receptor agonist among people with inadequately controlled type 2 diabetes.
Click here to read the full study: e.lilly/4jkBd6n
#MedSky #EndoSky
Click here to read the full study: e.lilly/4jkBd6n
#MedSky #EndoSky
I'm sharing our review on plasma biomarkers as a promising tool for identifying Alzheimer's disease pathology, including factors to consider prior to routine clinical use. Read more here: e.lilly/43Ok5Rt
#NeuroSky #MedSky
#NeuroSky #MedSky
April 25, 2025 at 9:00 PM
I'm sharing our review on plasma biomarkers as a promising tool for identifying Alzheimer's disease pathology, including factors to consider prior to routine clinical use. Read more here: e.lilly/43Ok5Rt
#NeuroSky #MedSky
#NeuroSky #MedSky
Behind every update is a team of dedicated HCPs—hi from the Lilly Medical social team! 👋
We’re here to keep U.S. healthcare providers informed with the latest clinical research and insights. Let’s keep learning together!
#MedSky
We’re here to keep U.S. healthcare providers informed with the latest clinical research and insights. Let’s keep learning together!
#MedSky
April 15, 2025 at 9:15 PM
Behind every update is a team of dedicated HCPs—hi from the Lilly Medical social team! 👋
We’re here to keep U.S. healthcare providers informed with the latest clinical research and insights. Let’s keep learning together!
#MedSky
We’re here to keep U.S. healthcare providers informed with the latest clinical research and insights. Let’s keep learning together!
#MedSky
I am sharing the latest results from the Phase 3 LUCENT study in patients with moderately to severely active Ulcerative Colitis #MedSky #GISky
Click here to read the full publication: https://e.lilly/4cbdmU0
Click here to read the full publication: https://e.lilly/4cbdmU0
April 10, 2025 at 9:00 PM
I am sharing the latest results from the Phase 3 LUCENT study in patients with moderately to severely active Ulcerative Colitis #MedSky #GISky
Click here to read the full publication: https://e.lilly/4cbdmU0
Click here to read the full publication: https://e.lilly/4cbdmU0
I’m sharing the TRAILBLAZER-ALZ-6 study—an ongoing Phase 3 trial in early symptomatic Alzheimer’s disease. See 24- and 52-week results of different dosing regimens of an amyloid-targeting therapy on ARIA and amyloid lowering. View the full publication here:https://e.lilly/4hpj2dN
#MedSky #NeuroSky
#MedSky #NeuroSky
April 4, 2025 at 9:00 PM
I’m sharing the TRAILBLAZER-ALZ-6 study—an ongoing Phase 3 trial in early symptomatic Alzheimer’s disease. See 24- and 52-week results of different dosing regimens of an amyloid-targeting therapy on ARIA and amyloid lowering. View the full publication here:https://e.lilly/4hpj2dN
#MedSky #NeuroSky
#MedSky #NeuroSky
I am sharing the latest results from the Phase 3 VIVID-1 study on quality-of-life outcomes in patients with Crohn's disease #MedSky #GIsky
Click here to read the full publication: https://e.lilly/4kW9MAZ
Click here to read the full publication: https://e.lilly/4kW9MAZ
March 28, 2025 at 4:47 PM
I am sharing the latest results from the Phase 3 VIVID-1 study on quality-of-life outcomes in patients with Crohn's disease #MedSky #GIsky
Click here to read the full publication: https://e.lilly/4kW9MAZ
Click here to read the full publication: https://e.lilly/4kW9MAZ